Complete remission with tyrosine kinase inhibitors in metastatic renal cell carcinoma

Mariam Benhami; Zineb Benbrahim; Lamiae Amaadour; Yassine El ouai; Karima Oualla; Samia Arifi; Nawfel Mellas

Volume : VIII, Issue : I, January - 2019

Complete remission with tyrosine kinase inhibitors in metastatic renal cell carcinoma

Mariam Benhami, Zineb Benbrahim, Lamiae Amaadour, Yassine El Ouai, Karima Oualla, Samia Arifi, Nawfel Mellas

Abstract :

We report a case of patient with disseminated metastatic clear-cell renal carcinoma (mCCR); who achieved radiological and metabolic complete response (CR) that lasted 3 years after starting Tyrosine Kinase Inhibitors therapy (TKI) with sunitinib then sorafenib . Durable clinical and pathological CRs are possible with targeted agents, even with disseminated metastases. Further researches are needed to define the optimal duration of systemic therapy in exceptional responders and identify the molecular determinants of response and resistance.